PharmaGap Inc. has developed novel drugs targeting Protein Kinase C (PKC). The Company’s pre-clinical lead drug candidate (GAP-107B8) is being developed to treat cancer. Aberrant over-expression of PKC is associated with many types of cancer and is a validated therapeutic target.

GAP-107B8 was developed employing proprietary computer models PharmaGap researchers have developed for select PKC isoforms. PharmaGap’s computer modeling abilities are a core competency and form the basis for the Company’s intellectual property and pipeline of drug compounds targeting PKC for the treatment of cancer and other diseases.

PharmaGap is pursuing a strategy to partner its lead drug candidates at the pre-clinical or early clinical trial stage.  The Company recognizes that its strengths rest in drug design and “proof of principle” validation and that larger pharmaceutical/biotech partners have the resources necessary to move the Company’s compounds into human clinical use.

PharmaGap is a spin-out from Canada’s premier biological research organization, the National Research Council of Canada. Offices and labs are located in Ottawa, Ontario, Canada.